EGF receptor trafficking: consequences for signaling and cancer

2013/11/29 by Alejandra Tomas, Alejandra Tomás, Clare E. Futter +1 · 2 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #HER2/EGFR in Cancer Research #Metabolism, Diabetes, and Cancer #Monoclonal and Polyclonal Antibodies Research

paper · pdf · doi:10.1016/j.tcb.2013.11.002

openalex publication_date 2013/11/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30

Abstract

The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively studied in the analysis of molecular mechanisms regulating endocytic traffic and the role of that traffic in signal transduction. Although such studies have largely focused on mitogenic signaling and dysregulated traffic in tumorigenesis, there is growing interest in the potential role of EGFR traffic in cell survival and the consequent response to cancer therapy. Here we review recent advances in our understanding of molecular mechanisms regulating ligand-stimulated EGFR activation, internalization, and post-endocytic sorting. The role of EGFR overexpression/mutation and new modulators of EGFR traffic in cancer and the response to cancer therapeutics are also discussed. Finally, we speculate on the relationship between EGFR traffic and cell survival.

Citations

• Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue

Cited by

• BiDAC-dependent degradation of plasma membrane proteins by the endolysosomal system
• E-cadherin endocytosis promotes non-canonical EGFR:STAT signalling to induce cell death and inhibit heterochromatinisation

Related

• Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery
• Investigating HER2/EGFR Signaling Dynamics and EV-Mediated Communication in Cancer Cells
• Spreading of EGF Receptor Activity into EGF-free Regions and Molecular Therapies of Cancer
• Extracellular Vesicles Provide a Real-Time Recording of Intracellular Signaling: EGFR receptor presence and implications for personalized therapy
• Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor–ErbB2 Heterodimers in Response to EGF Stimulation